Despite this, we still established a significant survival advantage in keeping with those previously reported with BET inhibitors and other novel epigenetic therapies in models of AML,7, 22 lymphoma9 and multiple myeloma.8 Moreover, at necropsy, tumor bulk was considerably lower in all recipient mice treated with I-BET, as evidenced by histology, peripheral white cell count and spleen weight (Figures 6e–g). This evidence concerns the gene DNER and plasma cell myeloma.